Fig. 3.

rOv-ASP-1 accelerates the influenza-specific antibody response. B6 mice were vaccinated with 0.3 μg of TIV, or TIV combined with 20 μg rOv-ASP-1. Influenza-specific total IgG levels in the plasma at weeks 1 and 2 were determined by ELISA using TIV as antigen. (A) OD₄₅₀ of plasma at week 1, and (B) titers of antibodies at weeks 1 and 2. (LOD is 31.25). The experiments were repeated 3 times (3–4 mice per group each time) with similar results. ^*p < 0.05, comparing OD₄₅₀ (A) or IgG titer (B) of TIV + rOv-ASP-1 vs TIV.